drugset / Trial / NCT06324435

Apremilast for Alcohol Use Disorder Treatment in Women and Men

NCT06324435

NaSingle-groupOpen-labelOther

Summary

For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).

Timeline

Start
2024-05-08
Primary completion
2026-08-30
Completion
2026-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 60 mg Oral